Control of material flow in the processing area was in adequate in that waste (b )(4) was carted through a door to the outside in the processing area and not provided for by the material flow written procedure .
Inspection Record
Changzhou SPL Company, Ltd — FDA 483 Findings
View the regulator's official source The source document is always the basis for judgement.
Findings
There is no report or data to show that leachables for the ( b)(4) bags used to hold Heparin Sodium USP lot, have been evaluated.
The outer foil bags containing Heparin Sodium USP lot ( b)(4) manufactured and held since 5/25/07, are not labeled.
A record as of the US FDA document published on 2024-01-17. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.